Background-Treatment and control of vascular risk factors reduce the likelihood of recurrent stroke. Present nationally representative data are sparse regarding secondary prevention treatment and control rates. Methods and Results-We evaluated sex-and race-stratified blood pressure, cholesterol, and hemoglobin A1c levels and treatment and control rates in 1154 self-reported stroke survivors from the National Health and Nutrition Examination Surveys 1999 to 2010. We used weighted linear regression to estimate time trends. Participants were 54% to 61% women, 70% to 76% white, and had a mean age of 63 to 66 years. For blood pressure, treatment rates remained unchanged in men, but in women, treatment rates increased from 41% in 1999 to 2000 to 65% in 2009 to 2010 (P=0.03), and control rates increased from 23% to 79% (P=0.03). Treatment rates remained unchanged in non-Hispanic whites, non-Hispanic blacks, and Mexican Americans, although control rates increased in non-Hispanic whites from 50% in 1999 to 2002 to 69% in 2007 to 2010 (P=0.04). For cholesterol, treatment rates increased from 30% to 40% in men (P=0.02) and from 28% to 36% (P<0.01) in women, but control rates increased only in men, from 62% to 87% (P<0.01). Cholesterol treatment rates increased only in non-Hispanic blacks, from 18% to 37% (P=0.02). By sex and race, there was no change in dysglycemia treatment and control. Conclusions-Despite improvements in blood pressure treatment and control and cholesterol treatment for women and cholesterol treatment and control for men, stroke secondary prevention through treatment and control of vascular risk factors remains suboptimal. Urgent action is needed to improve secondary prevention to reduce stroke morbidity and mortality in this high-risk group. 
R ecurrent strokes represent one quarter of the almost 800 000 strokes that occur in the United States each year, 1 and stroke subtypes have been associated with 1.5-to 6.6-fold increased risks for recurrent stroke during a mean follow-up of ≈4 years. 2 Secondary prevention that combines therapy for vascular factors, such as high blood pressure, high cholesterol, and diabetes mellitus, in addition to antiplatelet medications, 3 reduces the risk of recurrent stroke by 80%. 4 Initiating such therapy is thus important for these high-risk individuals.
Clinical trial evidence demonstrates the efficacy of targeting vascular factors, such as blood pressure and cholesterol, in stroke prevention, 5, 6 and guidelines published by the American Stroke Association (ASA) and American Heart Association (AHA) recommend treatment and control of each of these risk factors to prevent recurrent stroke. 1 Stroke secondary prevention treatment and control rates have ranged between 25% and 90% in prior studies, [7] [8] [9] but nationally representative data on stroke secondary prevention are sparse. We evaluated stroke secondary prevention treatment and control rates and antiplatelet/thrombotic therapy usage during a 12-year period in a nationally representative sample to define recent trends in stroke secondary prevention.
Methods

Study Sample
We analyzed cross-sectional data of all adults >20 years old from the National Health and Nutrition Examination Survey (NHANES), a nationally representative study of population health using interviews, physical examinations, and clinical testing. 10 From 1999 to 2010, data were released in six 2-year cycles (1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010) . Among the 62 160 participants in the 6 NHANES cycles from 1999 to 2010, we analyzed data from up to 1154 participants who self-reported a history of stroke. Participants were excluded if they did not participate in either the interview or examination (n=130). To analyze trends by race, consecutive NHANES cycles were combined into three 4-year cycles (1999-2002, 2003-2006, 2007-2010) according to NHANES analytic guidelines.
Study Variables
Methods of obtaining medical history, physical and lab examination measurements (including blood pressure, total cholesterol, high-density lipoprotein [HDL]-cholesterol, low-density lipoprotein [LDL]-cholesterol, fasting glucose, and hemoglobin A1c), and changes in measurement equipment and lab sites during the study period have been previously reported. 10 Coronary heart disease (CHD) was indicated by a self-report composite of CHD or myocardial infarction. End-stage renal disease was indicated by a history of dialysis. Malignant neoplasm was defined as any nonskin cancer except for melanoma. All other medical history was self-reported. Treatment rates were calculated based on self-report of pharmacotherapy for hypertension, hyperlipidemia, and diabetes mellitus. Control rates were defined as having a systolic blood pressure <140 mm Hg and a diastolic blood pressure <90 mm Hg (for hypertension), total cholesterol <5.2 mmol/L (<200 mg/dL; for hyperlipidemia), or hemoglobin A1c <7% (for diabetes mellitus). Total cholesterol, rather than LDL cholesterol, was chosen to define hyperlipidemia control rates because of the large amount of missing LDL data (N=679). Accordingly, analysis of lipid trends focused primarily on total cholesterol.
Statistical Analysis
All analyses were performed using SAS v.9.2 (SAS Institute, Cary, NC) and accounted for the complex-weighted sampling design of NHANES. Means and rates were calculated with PROC surveymeans and surveyfreq, accounting for stratum and cluster information where allowed by the sample size. In subgroups with small sample sizes, stratum and cluster information was removed from analysis when estimates did not converge. Full sample 2-year mobile examination center examination weight was used to calculate means and rates, except for analysis of glucose, where the fasting subsample 2-year mobile examination center weight was used. To estimate linear trends over time from 1999 to 2010, we used weighted linear regression with estimated mean values or percentages as dependent variables and survey time as independent variables. Reciprocals of variances were used as weights. Data are reported as mean and SE for continuous variables, or frequency and percentage for categorical variables, and are based on sampling weight. We further evaluated trends in treatment and control using logistic regression with time as a covariate and found similar results as weighted linear regressions (results not shown).
We also assessed for possible nonlinear trends in lipids and glucose, but not blood pressure, as previous evidence demonstrates linear changes in blood pressure over time. 12 For linear models with coefficient of determination (R 2 ) values <0.50, suggesting that the model explained relatively little of the variation in the outcome, we tested nonlinear trends by including a quadratic term for time in the linear model. Results of these tests showed minimal difference from standard linear models (only HDL-cholesterol in treated men [P=0.03] and total cholesterol in untreated women [P=0.03] were significant), so we used linear trends for simplicity. A 2-sided P value <0.05 defined statistical significance. Table 1 summarizes sample sizes and selected characteristics for stroke survivors from 1999 to 2000 to 2009 to 2010. The distribution of participant age, sex, and race/ethnicity was similar over time. Mean age ranged from 63 to 66 years, with an age range of 22 to 85 years, and more than half of stroke survivors were women. Non-Hispanic whites (70%-76%) were the most common racial/ethnic group, followed by nonHispanic blacks (12%-17%). The prevalence of heart disease, heart failure, cancer, and chronic bronchitis did not change over the study period, but the prevalence of diabetes mellitus increased from 22% to 28% (P for trend =0.05). Antiplatelet/ antithrombotic medication use increased from 24% to 34% (P for trend =0.05). Systolic blood pressure decreased from 138 to 126 mm Hg (P<0.01), and total cholesterol decreased from 5.40 to 4.79 mmol/L (P<0.01). Other measures of blood pressure, lipids, and glucose did not change over time.
Results
Blood Pressure
Mean systolic blood pressure for each NHANES cycle is presented in the Figure. Systolic blood pressure decreased from 134 to 125 mm Hg in men (P=0.03) and from 142 to 127 mm Hg in women (P=0.01). Mean diastolic blood pressure did not change over time in men or women (Table S1 in the online-only Data Supplement).
Hypertension treatment and control rates are listed by sex in Table 2 . In men, neither treatment nor control rates changed from 1999 to 2000 to 2009 to 2010. In women, treatment rates increased from 41% in 1999 to 2000 to 65% in 2009 to 2010 (P=0.03), whereas control rates in treated women increased from 23% to 79% (P<0.01). Blood pressure stratified by hypertension treatment status is also listed in Table 2 . In untreated men, mean systolic blood pressure decreased from 135 to 118 mm Hg, a decline of borderline statistical significance (P=0.06), whereas diastolic blood pressure did not change over time. In men receiving blood pressure treatment, systolic blood pressure decreased from 134 to 128 mm Hg (P=0.05), and diastolic blood pressure decreased from 75 to 66 mm Hg (P=0.04). Measures of blood pressure did not change over time in untreated women, but in treated women, systolic blood pressure decreased from 154 to 128 mm Hg (P<0.01), and diastolic blood pressure declined from 70 to 64 mm Hg (P=0.05).
Hypertension treatment and control rates are listed by race in Table S3 
WHAT THE STUDY ADDS
• This nationally representative analysis demonstrates that treatment and control of vascular risk factors have improved from 1999 to 2010, particularly in blood pressure for women and cholesterol for men.
• During this time period, minimal changes were seen across races in treatment and control of these risk factors in stroke survivors.
• Despite improvements over the last decade, significant room for improvement remains in treating and controlling vascular risk factors in individuals who have previously suffered a stroke.
non-Hispanic white individuals increased from 50% in 1999 to 2002 to 69% in 2007 to 2010 (P=0.04). The increase in control rates in untreated non-Hispanic white individuals from 64% to 84% (P=0.07) was accompanied by a decrease in systolic blood pressure from 134 to 122 mm Hg (P=0.02). The increase in control rates in treated non-Hispanic black individuals from 37% to 64% (P=0.07) was also associated with a decrease in diastolic blood pressure from 82 to 70 mm Hg (P=0.03). A decrease in diastolic blood pressure from 79 to 68 mm Hg (P=0.03) was also seen in untreated non-Hispanic black individuals. Control rates in untreated Mexican Americans increased from 80% to 94% (P=0.05), which was associated with a decrease in both systolic blood pressure from 128 to 115 mm Hg (P=0.02) and diastolic blood pressure from 69 to 65 mm Hg (P=0.02).
Cholesterol
Mean total cholesterol level for each NHANES cycle is shown in the Figure. In men, mean total cholesterol decreased from In both men and women overall, HDL generally increased and LDL generally decreased over time, although no trend was statistically significant (Table S1 in the online-only Data Supplement). Hyperlipidemia treatment and control rates are listed by sex in Table 3 . Among individuals receiving hyperlipidemia treatment across the study period, 61% to 92% of men and 58% to 77% of women were taking a statin (results not shown). In men, treatment rates increased from 30% in 1999 to 2000 to 40% in 2009 to 2010 (P=0.02), and control rates in treated men increased from 62% to 87% (P<0.01). Control rates in untreated men increased from 56% to 74% (P=0.04). In women, treatment rates increased from 28% in 1999 to 2000 to 36% in 2009 to 2010 (P<0.01), but control rates did not change across time.
Lipid measures stratified by hyperlipidemia treatment status are also listed in Table 3 . In untreated men, total cholesterol Table S1 in the online-only Data Supplement).
Diabetes mellitus treatment and control rates are shown by sex in Table 4 Diabetes mellitus treatment and control rates are listed by race in Table S5 in the online-only Data Supplement. There were no changes observed in treatment and control rates for non-Hispanic whites from 1999 to 2002 to 2007 to 2010, and no changes were seen in fasting glucose and HbA1c levels. No changes in treatment rates were seen in non-Hispanic blacks, although there was an increase in control rates in treated nonHispanic blacks from 42% to 61% (P=0.08). This change was associated with a decrease in fasting glucose (9.46-7.02 mmol/L; P=0.06) and a decrease in HbA1c (0.091-0.070; P=0.08). There were no changes in treatment or control in Mexican Americans.
Discussion
We present nationally representative data of treatment and control of blood pressure, cholesterol, and diabetes mellitus for stroke secondary prevention. From 1999 to 2010, hypertension treatment and control rates increased in women, with corresponding declines in systolic blood pressure. In men, treatment and control rates of blood pressure did not change over time, although systolic blood pressure decreased. Treatment rates did not change in non-Hispanic whites, non-Hispanic blacks, or Mexican Americans. Increases in control rates were seen particularly for non-Hispanic whites and non-Hispanic blacks. Increased treatment rates of hyperlipidemia in women did not correspond with an increase in control, although in men hyperlipidemia treatment rates increased from 30% to 40%, with concurrent increases in control. Hyperlipidemia treatment rates increased, particularly for non-Hispanic blacks, although declines in total cholesterol levels occurred mostly in non-Hispanic whites. Hyperglycemia treatment and control rates did not change in women or men or in any race groups. Antiplatelet/thrombotic medication use increased over time, but only 1 in 3 stroke survivors reported taking these medications. Although the observed trends in blood pressure and cholesterol control indicate positive changes, these results reflect suboptimal management of risk factors associated with recurrent stroke. A combination of healthful diet, physical activity, aspirin, statin, and blood pressure-lowering drugs has been projected to reduce the risk of recurrent vascular events in survivors of ischemic stroke by 80% 4 and represents a large opportunity for secondary prevention.
Blood pressure-lowering medications have been shown to reduce the risk of recurrent stroke or transient ischemic attack 13 and are class IA recommendations by the ASA/AHA for secondary prevention. 1 Blood pressure lowering has been associated with a 30% to 40% decrease in the risk of stroke, and risk reductions have been seen with a blood pressure reduction of ≈10/5 mm Hg on treatment, 1, 14 including in individuals with cerebrovascular disease. 15 Across the present study, only systolic blood pressure in women achieved similar reductions (an absolute decrease of 15 mm Hg). Observational data suggest that blood pressure is continuously associated with risk of recurrent stroke, down to low blood pressure levels (systolic 115 mm Hg). 16 Although increases in treatment rates, and treatment intensity as indicated by control, were seen across the study period, there remains a significant opportunity for stroke secondary prevention in targeting blood pressure. Cholesterol-lowering therapy is also recommended by the ASA/AHA for stroke secondary prevention, 1 although the effects of statins on lowering the risk for recurrent stroke are not yet completely established. A meta-analysis of the effect of statin use on the risk of both initial and recurrent stroke demonstrated a pooled reduction in risk of ≈20%. 17 The meta-analysis included the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, which demonstrated that aggressive treatment of elevated cholesterol (baseline total cholesterol ≈5.49 mmol/L or 212 mg/dL) with 80 mg atorvastatin reduced the risk of recurrent stroke. 18 On the contrary, a retrospective analysis by the Medical Research Council/British Heart Foundation Heart Protection Study reported in the meta-analysis also showed that 40 mg daily simvastatin treatment was associated with no reduction in the risk of recurrent stroke. 19 Nevertheless, ASA/AHA guidelines recommend statin therapy with intensive lipid-lowering effects to reduce the risk stroke in patients with ischemic stroke or transient ischemic attack, especially in those with atherosclerosis, as a class IB recommendation. Despite improvements from 1999 to 2010, including a notable increase in control rates in men to 87%, lipids remain undertreated in this high-risk group, and room for improvement remains in treatment and control, particularly in women. It is unclear whether the results of SPARCL or ASA/AHA guideline recommendations influenced practices and affected the results we observed.
The efficacy of intensive blood glucose control in reducing major macrovascular outcomes is unclear. Although some trials have demonstrated a reduction in major vascular outcomes, 20, 21 others report no reduction in cardiovascular events or death in groups receiving intensive glucose therapy. 22, 23 Nevertheless, diabetes mellitus has been identified as an independent predictor of recurrent stroke in populationbased studies, and an estimated 9.1% of recurrent strokes are attributable to diabetes mellitus. [24] [25] [26] The ASA/AHA guidelines suggest as a class IB recommendation the reduction of HbA1c to <7% through healthful diet, physical activity, and metformin therapy for high-risk individuals. 27 Although the increases in treatment and control by 2009 to 2010 indicate recent improvements in addressing dysglycemia, the low levels of treatment and control are discouraging and may have important implications for microvascular outcomes (eg, retinopathy, neuropathy, and nephropathy) that could increase comorbidities among stroke survivors.
Antiplatelet/thrombotic medications are a class IA recommendation for stroke secondary prevention, unless a contraindication is present, such as hemorrhagic stroke, gastric ulcers, or advanced liver disease. These drugs can reduce the risk of recurrent ischemic stroke by 25%, 3 but their low use (<40%) suggests an opportunity for improvement. Although the data from the present analysis should be interpreted with caution because approximately 13% of the stroke events in this analysis are likely to have been hemorrhagic, 28 overall the data presented here are consistent with previous analysis demonstrating that adherence to multidrug regimens for cardiovascular disease prevention is low 2 years after initiation of therapy.
29
Comparison With Other Forms of Cardiovascular Disease
Suboptimal treatment for secondary prevention of other forms of cardiovascular disease seems to be similarly common to stroke. Recent studies of treatment and prevention of CHD, for example, showed suboptimal but improving hypertension treatment levels. 30, 31 For instance, use of blood pressure-lowering medications in patients with CHD ranged from 23% to 60%, in comparison with 41% to 68% antihypertensive treatment rates in women and 51% to 68% treatment rates in men in our study. Similar treatment rates were also observed in selected registry data examining adherence to the AHA's Get With The Guidelines recommendations for secondary atherosclerosis prevention: blood pressure treatment was 17% to 73%, cholesterol treatment was 32%, and diabetes mellitus treatment was 45%. 32 An analysis of high-income countries showed that antihypertensive use in patients with cardiovascular disease ranged from 40% to 67%. 33 Our nationally representative data of stroke secondary prevention rates confirm that control of vascular risk factors in US stroke survivors is low.
Strengths and Limitations
Our study has several strengths, including a nationally representative sample and inclusion of major risk factors and treatments associated with reduced risk of recurrent stroke. 1 However, we note several limitations. First, we relied on selfreport of prior stroke (of unclear duration in these data) and present medical therapy to define treatment and control rates, both of which are subject to recall bias. However, of note, selfreport of stroke has been determined previously to have a positive predictive value of 79%, a sensitivity of about 80%, and specificity of 99%, 34 suggesting that self-reported stroke can reliably be used in epidemiological analysis. Further, population-based cohort studies, in a non-nationally representative setting in which stroke events are validated, show similarly low treatment rates for hypertension, hyperlipidemia, and diabetes mellitus. 35 Second, data on contraindications to secondary preventive therapies were not collected in NHANES. In a previous evaluation of adherence to secondary prevention therapies after ischemic stroke, contraindications accounted for only ≈5% of reasons for discontinuation of risk factor treatment. 36 Although the data in that study were limited, they indicate that contraindications likely contribute a modest amount to the large treatment gaps seen in the present evaluation. Third, we could not determine stroke type (ischemic versus cardioembolic versus hemorrhagic) among respondents, which may influence treatment recommendations by clinicians. Nonetheless, blood pressure, cholesterol, and glucose are targets for therapy in patients with most types of cardiovascular events. Fourth, our sample size was relatively small, which may have limited our ability to detect significant trends attributable to lack of power. However, because the United States currently lacks a national surveillance system to detect nonfatal cardiovascular events, 37 these data reflect representative results on recent stroke secondary prevention measures.
Conclusions
We present data from NHANES on stroke secondary prevention treatment and control rates for blood pressure, cholesterol, and glucose. Although modest improvements in management of these stroke risk factors were observed during the past decade, treatment and control remain suboptimal. These substantial gaps represent a significant missed opportunity for the prevention of adverse events in individuals at high risk for a particularly morbid disease, such as stroke. Action is needed to better understand limits to stroke secondary prevention. Mechanisms to improve treatment uptake, including outpatient quality improvement programs, pharmacist engagement, 38 innovative drug delivery systems such as a stroke polypill, and even novel financing mechanisms, 39 may increase patient access and adherence to stroke secondary preventive medicines.
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